Company intelligence / Profile preview

GenEditBio

Hong Kong, New Territories, Chinageneditbio.com ↗
Ownership
Private
Employees
~150
Development stage
Other
01

Overview

GenEditBio is developing precision gene editing technologies and is advancing toward clinical studies. The company recently secured strategic investment from Gobi Partners GBA to accelerate their research and development efforts.

Therapeutic areas
Rare Diseases
Modalities
Gene editingGene therapyCRISPR-based therapies
Industry
Biotech
02

Drug pipeline

3 assets

GEB-101

2

2 more assets in the full pipeline.

Beyond the preview

Go deeper on GenEditBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenEditBio.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call